Fig. 4From: The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumoursSLC7A5 mRNA and breast cancer patient outcome. a SLC7A5 vs breast-cancer-specific survival (BCSS) in all cases. b SLC7A5 vs BCSS in luminal A tumours. c SLC7A5 vs BCSS in luminal B tumours. d SLC7A5 vs BCSS in triple negative tumours. e SLC7A5 vs BCSS in human epidermal growth factor receptor 2 (HER2+) tumoursBack to article page